Core Viewpoint - The article highlights the significant advancements of Sanyuan Gene in the biopharmaceutical industry, showcasing its transition from traditional manufacturing to an Industry 4.0 standard smart factory, and emphasizes the importance of capital market support for innovation and growth [1][2][3]. Group 1: Company Development - Sanyuan Gene's new smart factory, built to Industry 4.0 standards, officially commenced production this year, marking a significant leap in its operational capabilities [1]. - The company has progressed through various stages of the capital market, from the New Third Board to the Beijing Stock Exchange, enhancing its governance structure along the way [2]. - The IPO has provided substantial funding for new drug research and development, while also increasing brand recognition and trust among patients and healthcare professionals [2][3]. Group 2: Product Innovation - Sanyuan Gene's core product, the recombinant human interferon α1b series, has seen a sales increase of over 10 times in the first three quarters of this year, attributed to national procurement policies [3]. - The company emphasizes the importance of drug accessibility and adherence, particularly with its easy-to-use spray formulation, which enhances patient compliance [3]. - In the pediatric medication sector, Sanyuan Gene has made significant contributions, especially during viral outbreaks, by providing effective treatments [3]. Group 3: Technological Advancements - The new smart factory is recognized as a key project in Beijing's technological innovation and is expected to be an advanced intelligent factory by 2025 [3][5]. - The digital quality control system implemented in the factory ensures product quality stability and consistency while enhancing production capacity [5]. - All equipment and instruments in the factory are domestically produced, reflecting the company's commitment to local manufacturing [5]. Group 4: Research and Development Focus - Sanyuan Gene plans to allocate 14.52% of its revenue to R&D in the first half of 2025, focusing on two major projects: new PEG-integrated interferon and γδT cell therapy for tumors [6]. - The company aims to achieve clinical cure for chronic hepatitis B through its innovative interferon development [6]. - In oncology, Sanyuan Gene is exploring the application of γδT cells in treating hematological malignancies, particularly in hard-to-treat tumors [6]. Group 5: Future Vision - Sanyuan Gene is committed to making affordable medications accessible to the public, having successfully reduced the price of its interferon from 300 yuan to around 30 yuan [6]. - The company aims to transition from cytokine drugs to cell therapy drugs, continuing its innovation to support the health of the Chinese population [6].